tetano
Editor, Senior Moderator
Open Forum Infect Dis. 2015 Jan 3;2(1)
fu115. doi: 10.1093/ofid/ofu115. eCollection 2015.
[h=1]Comparison of serum hemagglutinin and neuraminidase inhibition antibodies after 2010-2011 trivalent inactivated influenza vaccination in healthcare personnel.[/h] Laguio-Vila MR[SUP]1[/SUP], Thompson MG[SUP]2[/SUP], Reynolds S[SUP]2[/SUP], Spencer SM[SUP]2[/SUP], Gaglani M[SUP]3[/SUP], Naleway A[SUP]4[/SUP], Ball S[SUP]5[/SUP], Bozeman S[SUP]5[/SUP], Baker S[SUP]6[/SUP], Mart?nez-Sobrido L[SUP]6[/SUP], Levine M[SUP]2[/SUP], Katz J[SUP]2[/SUP], Fry AM[SUP]2[/SUP], Treanor JJ[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Background. Most inactivated influenza vaccines contain purified and standardized hemagglutinin (HA) and residual neuraminidase (NA) antigens. Vaccine-associated HA antibody responses (hemagglutination inhibition [HAI]) are well described, but less is known about the immune response to the NA. Methods. Serum of 1349 healthcare personnel (HCP) electing or declining the 2010-2011 trivalent-inactivated influenza vaccine ([IIV3], containing A/California/7/2009 p(H1N1), A/Perth/16/2009 [H3N2], B/Brisbane/60/2008 strains) were tested for NA-inhibiting (NAI) antibody by a modified lectin-based assay using pseudotyped N1 and N2 influenza A viruses with an irrelevant (H5) HA. Neuraminidase-inhibiting and HAI antibody titers were evaluated approximately 30 days after vaccination and end-of-season for those with polymerase chain reaction (PCR)-confirmed influenza infection. Results. In 916 HCP (68%) receiving IIV3, a 2-fold increase in N1 and N2 NAI antibody occurred in 63.7% and 47.3%, respectively. Smaller responses occurred in HCP age >50 years and those without prior 2009-2010 IIV3 nor monovalent A(H1N1)pdm09 influenza vaccinations. Forty-four PCR-confirmed influenza infections were observed, primarily affecting those with lower pre-exposure HAI and NAI antibodies. Higher pre-NAI titers correlated with shorter duration of illness for A(H1N1)pdm09 virus infections. Conclusions. Trivalent-inactivated influenza vaccine is modestly immunogenic for N1 and N2 antigens in HCP. Vaccines eliciting robust NA immune responses may improve efficacy and reduce influenza-associated morbidity.
[h=4]KEYWORDS:[/h] antibody; hemagglutinin-inhibition; influenza; neuraminidase-inhibition; vaccine
PMID: 25884004 [PubMed] PMCID: PMC4396428
fu115. doi: 10.1093/ofid/ofu115. eCollection 2015.[h=1]Comparison of serum hemagglutinin and neuraminidase inhibition antibodies after 2010-2011 trivalent inactivated influenza vaccination in healthcare personnel.[/h] Laguio-Vila MR[SUP]1[/SUP], Thompson MG[SUP]2[/SUP], Reynolds S[SUP]2[/SUP], Spencer SM[SUP]2[/SUP], Gaglani M[SUP]3[/SUP], Naleway A[SUP]4[/SUP], Ball S[SUP]5[/SUP], Bozeman S[SUP]5[/SUP], Baker S[SUP]6[/SUP], Mart?nez-Sobrido L[SUP]6[/SUP], Levine M[SUP]2[/SUP], Katz J[SUP]2[/SUP], Fry AM[SUP]2[/SUP], Treanor JJ[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Background. Most inactivated influenza vaccines contain purified and standardized hemagglutinin (HA) and residual neuraminidase (NA) antigens. Vaccine-associated HA antibody responses (hemagglutination inhibition [HAI]) are well described, but less is known about the immune response to the NA. Methods. Serum of 1349 healthcare personnel (HCP) electing or declining the 2010-2011 trivalent-inactivated influenza vaccine ([IIV3], containing A/California/7/2009 p(H1N1), A/Perth/16/2009 [H3N2], B/Brisbane/60/2008 strains) were tested for NA-inhibiting (NAI) antibody by a modified lectin-based assay using pseudotyped N1 and N2 influenza A viruses with an irrelevant (H5) HA. Neuraminidase-inhibiting and HAI antibody titers were evaluated approximately 30 days after vaccination and end-of-season for those with polymerase chain reaction (PCR)-confirmed influenza infection. Results. In 916 HCP (68%) receiving IIV3, a 2-fold increase in N1 and N2 NAI antibody occurred in 63.7% and 47.3%, respectively. Smaller responses occurred in HCP age >50 years and those without prior 2009-2010 IIV3 nor monovalent A(H1N1)pdm09 influenza vaccinations. Forty-four PCR-confirmed influenza infections were observed, primarily affecting those with lower pre-exposure HAI and NAI antibodies. Higher pre-NAI titers correlated with shorter duration of illness for A(H1N1)pdm09 virus infections. Conclusions. Trivalent-inactivated influenza vaccine is modestly immunogenic for N1 and N2 antigens in HCP. Vaccines eliciting robust NA immune responses may improve efficacy and reduce influenza-associated morbidity.
[h=4]KEYWORDS:[/h] antibody; hemagglutinin-inhibition; influenza; neuraminidase-inhibition; vaccine
PMID: 25884004 [PubMed] PMCID: PMC4396428